Injection site reactions, separate from general skin effects, can occur
AOD-9604 is a modified fragment of human growth hormone (hGH), derived from the C-terminal region commonly described as hGH 176191 (sometimes written as Tyr-hGH 177191)
The patient population of this study when we talk about random controlled trials, there were 3 patients in the study
The FDA found that problematic since clinical trials only tested the peptide at 2 mg/mL
BehemothLabz Disclaimer Please make sure you go through the Terms and Conditions, and please familiarize yourself with them as they are important
* Different dose-escalation schemes were used for 36 and 45 mg slow and rapid dose escalation to final doses, ** both once weekly and twice weekly dosing were trialed, different dose-escalation schemes were used for doses 4, 8 and 12 mg